Nature子刊：苏佳灿/陈小元/魏彦/白龙团队开发新型纳米药物，精准治疗骨关节炎

Core Viewpoint - The article discusses a significant advancement in the development of disease-modifying osteoarthritis drugs (DMOADs) through a novel drug delivery system that effectively targets diseased chondrocytes, addressing major challenges in osteoarthritis treatment [1][2]. Group 1 - A multifunctional peptide (CMP) mimicking viral glycoproteins was developed to enhance drug delivery to osteoarthritic chondrocytes, overcoming issues related to cartilage penetration, retention, and selective uptake by diseased cells [2][5]. - The research team synthesized CMP, which includes a type II collagen adhesion sequence and a cell-penetrating peptide activated by matrix metalloproteinase-13, allowing the drug-loaded micelles to adhere to cartilage and selectively target diseased chondrocytes [5]. - In mouse models of osteoarthritis, the developed micelles demonstrated longer joint retention times and higher uptake rates in diseased chondrocytes compared to unmodified micelles, indicating improved efficacy [5]. Group 2 - The drug delivery system maintained cartilage metabolic homeostasis, alleviated pathological changes associated with osteoarthritis, and improved symptoms without causing additional toxicity [2][5]. - Overall, the findings suggest that the developed nanomedicine represents a promising candidate for DMOADs and provides an efficient delivery strategy for targeting other therapeutic agents to diseased chondrocytes [2][5].